NEW YORK, June 28 - Qiagen and Aventis have signed a technology access agreement for Qiagen's new ZeptoGene Workstation microarray platform, Qiagen said Thursday. 

Under the agreement, Aventis will acquire limited access to the platform, which can be used for both nucleic acid and protein analysis.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.